Showing 7 articles tagged 'Immunotherapy':
The Institute of Cancer Research has discovered a genetic mutation in samples of some men's tumours that could make them particularly susceptible to immunotherapy treatment. The researchers are now committed to running clinical trials to prove if their theory is right.
Preventing resistance to hormone therapy is a key goal for researchers trying to improve prostate cancer treatment. Now, research funded by us – thanks to your donations – has revealed that the immune system could have a part to play.
An early-stage trial of the immunotherapy drug, pembrolizumab, has proven it to be effective for a small number of men with incurable disease. We take a closer a look at how it works and what we're doing to bring the benefits of immunotherapy to many more men with prostate cancer.
With prostate cancer now the third biggest cancer killer, it is clearer than ever that we need big leaps forward. That’s why we’re awarding £2.7 million to UK scientists to fund some of the most exciting and revolutionary ideas.
BLOG: We're only 12 months into our ten-year strategy to tame prostate cancer, but that doesn't mean we haven't already made exciting progress. Our resident expert, Dr Ian Le Guillou, gives us his top ten biggest research breakthroughs (in no particular order) from 2016.
BLOG: In 2013, the prestigious Science magazine nominated cancer immunotherapy as their ‘breakthrough of the year’. This came after positive results from clinical trials in skin cancer and leukemia patients showed its potential as a completely new way to treat cancer. Sophie Lutter investigates and asks if immunotherapy has a future as a way of treating prostate cancer.
BLOG: Sophie Lutter follows up our feature on immunotherapy, an exciting new area of cancer research, with a run down of the research we're supporting into immunotherapy for prostate cancer.